FROM Timothy McBride
Can politics cure the high cost of drugs? EpiPens are the poster child for vast increases in the price of familiar medications. Many people carry them for emergency treatment of allergic reactions that can be life threatening. So, when the Mylan Company raised the price of two EpiPens from $100 $614 it made big news. Turns out, it's the tip of the iceberg. Drug prices are on the rise and desperately ill people are often those hit by bills they never expected. Other countries have established price controls for life-or-death medications, but America's system is so complex it defies understanding. Drug and insurance companies, hospitals and doctors engage in secret negotiations, while various middlemen get cuts of the action. And, who's paying for those expensive ads on TV? Patients. Are the presidential campaigns offering any realistic solutions?
Trump plays scolder-in-chief with NATO allies At the opening of NATO’s dramatic new headquarters in Brussels today, President Trump acknowledged that Article 5 — promising that “an attack on one nation is an attack on all” -- has only been invoked one time: in the aftermath of September 11. But the President failed to provide what 27 other Alliance members have been waiting for: a re-commitment by America’s new leader to Article 5. Instead, they got a scolding.
Who's to blame for the opioid crisis? Some of the lawyers who took on Big Tobacco are now going after Big Pharma. It’s all about the deadly epidemic of opioid use. Are the drug companies to blame? What about the users? Later, on today’s Talking Point: making sense of Britain’s upset election.
Replacing Obamacare: Now you see it… now you don’t As the Senate deliberates replacing Obmacare, health coverage for millions of people is at stake. There've been no public hearings, and a draft measure won't be made public. Is the House version so unpopular that that Senate is hiding a version that looks much the same?